Novel rapid diagnostic tests (RDTs) offer huge potential to optimise clinical care and improve patient outcomes. In this study, we aim to assess the current patterns of use around the world, identify issues for successful implementation and suggest best practice advice on how to introduce new tests. An electronic survey was devised by the International Society of Antimicrobial Chemotherapy (ISAC) Rapid Diagnostics and Biomarkers working group focussing on the availability, structure and impact of RDTs around the world. It was circulated to ISAC members in December 2019. Results were collated according to the UN human development index (HDI). 81 responses were gathered from 31 different countries. 84% of institutions reported the availability of any test 24/7. In more developed countries, this was more for respiratory viruses, whereas in high and medium/low developed countries, it was for HIV and viral hepatitis. Only 37% of those carrying out rapid tests measured the impact. There is no ‘one-size fits all’ solution to RDTs: the requirements must be tailored to the healthcare setting in which they are deployed and there are many factors that should be considered prior to this.

新型快速诊断测试 (RDT) 为优化临床护理和改善患者治疗结果提供了巨大潜力。在这项研究中，我们的目标是评估世界各地当前的使用模式，确定成功实施的问题，并就如何引入新测试提出最佳实践建议。国际抗菌化疗协会 (ISAC) 快速诊断和生物标志物工作组设计了一项电子调查，重点关注全球 RDT 的可用性、结构和影响。该报告于 2019 年 12 月分发给 ISAC 成员。结果根据联合国人类发展指数 (HDI) 进行整理。收集了来自 31 个不同国家的 81 份回复。 84% 的机构表示可以 24/7 进行任何测试。在较发达国家，这更多地针对呼吸道病毒，而在高发达国家和中/低发达国家，则针对艾滋病毒和病毒性肝炎。在进行快速测试的人中，只有 37% 的人测量了影响。 RDT 不存在“一刀切”的解决方案：必须根据部署 RDT 的医疗保健环境量身定制要求，并且在此之前应考虑许多因素。